Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-25T11:42:17.844Z Has data issue: false hasContentIssue false

Can head and neck cancer patients be discharged after three years?

Published online by Cambridge University Press:  10 October 2013

R Kumar*
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Cumberland Infirmary, Carlisle, UK
G Putnam
Affiliation:
Department of Maxillofacial Surgery, Cumberland Infirmary, Carlisle, UK
P Dyson
Affiliation:
Department of Oncology, Cumberland Infirmary, Carlisle, UK
A K Robson
Affiliation:
Department of Otolaryngology-Head and Neck Surgery, Cumberland Infirmary, Carlisle, UK
*
Address for correspondence: Mr R Kumar, Department of Otolaryngology–Head and Neck Surgery, Cumberland Infirmary, Newtown Rd, Carlisle CA2 7HY, UK E-mail: drrohitkumar@doctors.org.uk

Abstract

Background:

Follow-up surveillance of head and neck cancer patients varies throughout the UK. The heterogeneity of these patients limits the applicability of a standardised protocol. Improvements in our understanding of the natural history of the disease may assist in the tailoring of resources to patients.

Method:

Prospective data collected at the Cumberland Infirmary over a 13-year period were analysed, primarily focusing upon recurrence rates and time to recurrence.

Results:

In keeping with other studies, recurrence of head and neck squamous cell carcinoma was found to be maximal within the first three years of treatment, regardless of subsite.

Conclusion:

Hospital-based surveillance may be safely discontinued after three years for some patients. Laryngeal carcinoma may require further surveillance due to possible delayed recurrence of a second primary formation. Emphasis must be placed on patient education, accessibility to head and neck services, and the existence of a robust system to facilitate urgent referrals.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Joshi, A, Calman, F, O'Connell, M, Jeannon, JP, Pracy, P, Simo, R.Current trends in the follow-up of head and neck cancer patients in the UK. Clin Oncol (R Coll Radiol) 2010;22:114–18CrossRefGoogle ScholarPubMed
2Argiris, A, Karamouzis, MV, Raben, D, Ferris, RL. Head and neck cancer. Lancet 2008;371:1695–709CrossRefGoogle ScholarPubMed
3NHS Modernisation Agency. 10 High Impact Changes for Service Improvement and Delivery: A Guide for NHS Leaders. London: Department of Health Publications, 2004Google Scholar
4Allen, A.The meaning of the breast cancer follow-up experience for the women who attend. Eur J Oncol Nurs 2002;6:155–61CrossRefGoogle ScholarPubMed
5Boysen, M, Natvig, K, Winther, FO, Tausjo, J. Value of routine follow-up in patients treated for squamous cell carcinoma of the head and neck. J Otolaryngol 1985;14:211–14Google ScholarPubMed
6de Visscher, AV, Manni, JJ. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense? Arch Otolaryngol Head Neck Surg 1994;120:934–9CrossRefGoogle ScholarPubMed
7Kothari, P, Trinidade, A, Hewitt, RJ, Singh, A, O'Flynn, P. The follow-up of patients with head and neck cancer: an analysis of 1,039 patients. Eur Arch Otorhinolaryngol 2011;268:1191–200CrossRefGoogle Scholar
8Haas, I, Hauser, U, Ganzer, U.The dilemma of follow-up in head and neck cancer patients. Eur Arch Otorhinolaryngol 2001;258:177–83CrossRefGoogle ScholarPubMed
9Lester, SE, Wight, RG. ‘When will I see you again?’ Using local recurrence data to develop a regimen for routine surveillance in post-treatment head and neck cancer patients. Clin Otolaryngol 2009;34:546–51CrossRefGoogle Scholar
10Boysen, M, Lovdal, O, Tausjo, J, Winther, F. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 1992;28:426–30CrossRefGoogle ScholarPubMed
11Cooney, TR, Poulsen, MG.Is routine follow-up useful after combined-modality therapy for advanced head and neck cancer? Arch Otolaryngol Head Neck Surg 1999;125:379–82CrossRefGoogle ScholarPubMed
12Hong, AM, Dobbins, TA, Lee, CS, Jones, D, Harnett, GB, Armstrong, BK et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010;103:1510–17CrossRefGoogle ScholarPubMed
13Sedaghat, AR, Zhang, Z, Begum, S, Palermo, R, Best, S, Ulmer, KM et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009;119:1542–9CrossRefGoogle ScholarPubMed
14van der Laan, BF, Baris, G, Gregor, RT, Hilgers, FJ, Balm, AJ. Radiation-induced tumours of the head and neck. J Laryngol Otol 1995;109:346–9CrossRefGoogle ScholarPubMed